Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2013 2
2014 1
2015 3
2016 7
2017 10
2018 10
2019 15
2020 11
2021 17
2022 17
2023 21

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Inflammation and immunity in IPF pathogenesis and treatment.
Heukels P, Moor CC, von der Thüsen JH, Wijsenbeek MS, Kool M. Heukels P, et al. Among authors: wijsenbeek ms. Respir Med. 2019 Feb;147:79-91. doi: 10.1016/j.rmed.2018.12.015. Epub 2019 Jan 9. Respir Med. 2019. PMID: 30704705 Free article. Review.
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.
Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM; 1305-0013 Trial Investigators. Richeldi L, et al. Among authors: wijsenbeek ms. N Engl J Med. 2022 Jun 9;386(23):2178-2187. doi: 10.1056/NEJMoa2201737. Epub 2022 May 15. N Engl J Med. 2022. PMID: 35569036 Clinical Trial.
Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis.
Marinescu DC, Raghu G, Remy-Jardin M, Travis WD, Adegunsoye A, Beasley MB, Chung JH, Churg A, Cottin V, Egashira R, Fernández Pérez ER, Inoue Y, Johannson KA, Kazerooni EA, Khor YH, Lynch DA, Müller NL, Myers JL, Nicholson AG, Rajan S, Saito-Koyama R, Troy L, Walsh SLF, Wells AU, Wijsenbeek MS, Wright JL, Ryerson CJ. Marinescu DC, et al. Among authors: wijsenbeek ms. Chest. 2022 Sep;162(3):614-629. doi: 10.1016/j.chest.2022.06.013. Epub 2022 Jun 20. Chest. 2022. PMID: 35738345 Review.
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U. Lancaster LH, et al. Among authors: wijsenbeek ms. Eur Respir Rev. 2017 Dec 6;26(146):170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Eur Respir Rev. 2017. PMID: 29212837 Free PMC article. Review.
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Leard LE, Holm AM, Valapour M, Glanville AR, Attawar S, Aversa M, Campos SV, Christon LM, Cypel M, Dellgren G, Hartwig MG, Kapnadak SG, Kolaitis NA, Kotloff RM, Patterson CM, Shlobin OA, Smith PJ, Solé A, Solomon M, Weill D, Wijsenbeek MS, Willemse BWM, Arcasoy SM, Ramos KJ. Leard LE, et al. Among authors: wijsenbeek ms. J Heart Lung Transplant. 2021 Nov;40(11):1349-1379. doi: 10.1016/j.healun.2021.07.005. Epub 2021 Jul 24. J Heart Lung Transplant. 2021. PMID: 34419372 Free PMC article.
Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial.
West A, Chaudhuri N, Barczyk A, Wilsher ML, Hopkins P, Glaspole I, Corte TJ, Šterclová M, Veale A, Jassem E, Wijsenbeek MS, Grainge C, Piotrowski W, Raghu G, Shaffer ML, Nair D, Freeman L, Otto K, Montgomery AB. West A, et al. Among authors: wijsenbeek ms. Thorax. 2023 Sep;78(9):882-889. doi: 10.1136/thorax-2022-219391. Epub 2023 Mar 22. Thorax. 2023. PMID: 36948586 Free article. Clinical Trial.
Idiopathic pulmonary fibrosis.
Koudstaal T, Wijsenbeek MS. Koudstaal T, et al. Among authors: wijsenbeek ms. Presse Med. 2023 May 6;52(3):104166. doi: 10.1016/j.lpm.2023.104166. Online ahead of print. Presse Med. 2023. PMID: 37156412 Free article.
Treatment of Sarcoidosis.
Wijsenbeek MS, Culver DA. Wijsenbeek MS, et al. Clin Chest Med. 2015 Dec;36(4):751-67. doi: 10.1016/j.ccm.2015.08.015. Clin Chest Med. 2015. PMID: 26593147 Review.
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Santin-Janin H, Mulder GJ, Bartholmai B, Gupta R, Richeldi L. Raghu G, et al. Among authors: wijsenbeek ms. JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129. JAMA. 2018. PMID: 29800034 Free PMC article. Clinical Trial.
Management of Idiopathic Pulmonary Fibrosis.
Salisbury ML, Wijsenbeek MS. Salisbury ML, et al. Among authors: wijsenbeek ms. Clin Chest Med. 2021 Jun;42(2):275-285. doi: 10.1016/j.ccm.2021.03.004. Clin Chest Med. 2021. PMID: 34024403 Review.
110 results